Galectin Thera
Stock
Stock
ISIN: US3632252025
Ticker: GALT
US3632252025
GALT
Price
Price
CHART BY
Frequently asked questions
What is Galectin Thera's market capitalization?
The market capitalization of Galectin Thera is $70.41M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for Galectin Thera?
Galectin Thera's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$0.728. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Galectin Thera's stock?
Currently, 1 analysts cover Galectin Thera's stock, with a consensus target price of $11.00. Analyst ratings provide insights into the stock's expected performance.
What is the EBITDA for Galectin Thera?
Galectin Thera's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$39.53M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Galectin Thera?
Galectin Thera has a free cash flow of -$33.68M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Galectin Thera have, and what sector and industry does it belong to?
Galectin Thera employs approximately 14 people. It operates in the Health Care sector, specifically within the Biotechnology industry.
What is the free float of Galectin Thera's shares?
The free float of Galectin Thera is 43.36M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $70.41M
- EPS (TTM)
- -$0.728
- Free Float
- 43.36M
- EBITDA (TTM)
- -$39.53M
- Free Cashflow (TTM)
- -$33.68M
Pricing
- 1D span
- $1.076$1.184
- 52W span
- $0.738$4.26
Analyst Ratings
The price target is $11.00 and the stock is covered by 1 analysts.
Buy
0
Hold
1
Sell
0
Information
Galectin Therapeutics, Inc. is a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease, severe skin disease, and cancer. Its programs target the development of carbohydrate molecules which offers alternative options to larger market segments. The company was founded by James C. Czirr and Anatole A. Klyosov on July 10, 2000 and is headquartered in Norcross, GA.
- Employees
- 14
- Industries
- Biotechnology
- Sector
- Health Care
Identifier
- ISIN
- US3632252025
- Primary Ticker
- GALT